Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNC | P24863 | 14/20 | 0.58 |
| ▸ | CDK8 | P49336 | 14/20 | 0.58 |
| ▸ | CDK19 | Q9BWU1 | 14/20 | 0.58 |
| ▸ | CDK9 | P50750 | 1/20 | 0.58 |
| ▸ | IKBKB | O14920 | 5/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | BTK | Q06187 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6990260 | 0.91 | CCNC (0.59) | CCNCCDK8CDK19CDK9KDM4E | |
| SCHEMBL6991483 | 0.82 | CCNC (0.65) | CCNCCDK8CDK19CDK9KDM4E | |
| SCHEMBL18429198 | 0.74 | CCNC (1.00) | CCNCCDK8CDK19CDK9 | |
| SCHEMBL6993426 | 0.74 | CCNC (0.48) | CCNCCDK8CDK19CDK9CYP1A2 | |
| SCHEMBL6990354 | 0.73 | CCNC (0.64) | CCNCCDK8CDK19CDK9KDM4E | |
| SCHEMBL6999101 | 0.70 | CCNC (0.49) | CCNCCDK8CDK19CDK9KDM4E | |
| SCHEMBL7241443 | 0.68 | CCNC (1.00) | CCNCCDK8CDK19CDK9 | |
| SCHEMBL18429103 | 0.68 | CCNC (1.00) | CCNCCDK8CDK19CDK9KDM4E | |
| SCHEMBL7243276 | 0.68 | CCNC (0.61) | CCNCCDK8CDK19CDK9KDM4E | |
| SCHEMBL18429383 | 0.66 | CCNC (1.00) | CCNCCDK8CDK19CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0931074-B1 | CONDENSED 4,5,6,7-TETRAHYDROBENZO C]THIOPHENES AS ENHANCER FOR CELL DIFFERENTIATION INDUCTION FACTOR ACTION | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2003-05-07 | — | — | EP | disclosed |
| US-6489351-B1 | POSSESSES CELL DIFFERENTIATION INDUCING FACTOR ACTION-ENHANCING ACTIVITY AND ANTI-MATRIX METALLOPROTEASE ACTIVITY AND THAT IS USEFUL IN THE PREVENTION AND TREATMENT OF BONE DISEASES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-12-03 | — | — | US | disclosed |
| US-6391905-B1 | 4,5-DIHYDRO-8-METHYLTHIO-2-PHENYLFURO(3,4-E)BENZOTHIAZOLE-6-CA RBOXYLIC ACID, FOR EXAMPLE; ANTI-MATRIX METALLOPROTEASE ACTIVITY; FOR BONE DISEASES SUCH AS OSTEOPOROSIS, RHEUMATOID ARTHRITIS, CANCER METASTASIS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-05-21 | — | — | US | disclosed |
| US-20020049242-A1 | Condensed 4,5,6,7-tetrahydrobenzo[C]thiopenes as enhancer for cell differentiation induction factor action | TAKEDA PHARMACEUTICAL COMPANY, LIMITED (JP) | 2002-04-25 | — | — | US | disclosed |
| US-6242471-B1 | BONE DISORDERS, OSTEOPOROSIS, RHEUMATOID ARTHRITIS, ARTERIOSCLEROSIS, CANCER METASTASIS, NERVOUS SYSTEM AND BRAIN DISORDERS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-06-05 | — | — | US | disclosed |
| US-6066658-A | FOR PREVENTION AND TREATMENT OF BONE DISEASES SUCH AS OSTEOPOROSIS, BONE FRACTURES, OSTEOARTHRITIS AND RHEUMATOID ARTHRITIS, ARTERIOSCLEROSIS, CANCER METASTASIS, AND DISEASES BASED ON NERVE DEGENERATION | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049242-A1 | Condensed 4,5,6,7-tetrahydrobenzo[C]thiopenes as enhancer for cell differentiation induction factor action | ACIN1, NFE2, NFE2L2 | CCNC 867/4885CDK8 1156/4885CDK19 2251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.